GlaxoSmithKline has made a $2.6 billion unsolicited offer to take over Human Genome Sciences, reports Brett Chase at Miyanville. But not only has Human Genome rejected Glaxo's offer, it put itself up for sale to the highest bidder, saying Glaxo's offer of $13 a share is too low and doesn't reflect the potential value of the company.